<a href="https://laohu8.com/S/NNVC">NanoViricides Inc.</a> Advances NV-387 into Phase II Clinical Trials for Potential Cancer Resurgence and Viral Infection Treatment
NanoViricides Inc., a publicly traded company and clinical stage pioneer in broad-spectrum antivirals, has announced advancements in the clinical trials of its antiviral drug NV-387. The drug, which has completed a Phase I clinical trial, is now moving into Phase II trials. NV-387 has shown potential in reducing the resurgence of metastatic cancer by mitigating inflammation, particularly through the reduction of IL-6, an inflammatory marker. The drug has demonstrated significant protective effects on lungs in animal models with lethal viral infections, outperforming existing antiviral treatments like Tamiflu, Rapivab, and Xofluza in these studies. Results from the Phase I trial have been presented, while further results from the Phase II trials are anticipated in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1061948) on August 18, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。